Related Experiment Video
Updated: Jun 12, 2026
07:45
A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
Published on: November 8, 2014
Virtual Screening and Zebrafish Phenotype-Based Evaluation Argues Against Repurposing 4-Phenylbutyrate for
Aline Frick1,2, Paige Whyte-Fagundes1, Scott C Baraban1,3
1Department of Neurological Surgery & Weill Institute for Neuroscience, University of California, San Francisco, San Francisco, California, USA.
Pharmacology Research & Perspectives
|June 10, 2026
Summary
4-phenylbutyrate (4-PBA) did not improve movement or epilepsy in zebrafish models of Syntaxin-binding protein 1 (STXBP1) disorders. These findings caution against using 4-PBA for treating STXBP1-related conditions.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Syntaxin-binding protein 1 (STXBP1) mutations cause severe neurological disorders, including epilepsy and intellectual disability.
- Current treatments for STXBP1 disorders are lacking.
- Previous C. elegans studies suggested 4-phenylbutyrate (4-PBA) as a potential therapeutic agent.
Purpose of the Study:
- To evaluate the efficacy of 4-PBA and AI-identified analogs in zebrafish models of STXBP1 disorders.
- To assess the potential of 4-PBA as a repurposed drug for STXBP1-related conditions.
Main Methods:
- Utilized a stxbp1a zebrafish model to assess locomotion and response to 4-PBA and 16 candidate compounds.
- Employed automated locomotion assays in larval zebrafish.
- Conducted electrophysiology studies in a stxbp1b zebrafish model to evaluate seizure activity.
Main Results:
- The stxbp1a zebrafish model exhibited a pronounced movement disorder.
- 4-PBA and candidate compounds failed to rescue the locomotion deficits in stxbp1a mutants.
- 4-PBA treatment did not reduce seizure-like events in the stxbp1b zebrafish model.
Conclusions:
- 4-phenylbutyrate (4-PBA) and related compounds are not effective in rescuing motor deficits or epilepsy in STXBP1 zebrafish models.
- Repurposing 4-PBA for STXBP1 disorders requires further investigation and caution.
- These findings highlight the need for alternative therapeutic strategies for STXBP1-related neurological conditions.
